SELECTA BIOSCIENCES, INC. (NASDAQ:SELB) Files An 8-K Submission of Matters to a Vote of Security Holders

SELECTA BIOSCIENCES, INC. (NASDAQ:SELB) Files An 8-K Submission of Matters to a Vote of Security Holders

Story continues below

Item 5.07. Submission of Matters to a Vote of Security Holders.

On June 16, 2017, Selecta Biosciences, Inc. (the Company) held
its Annual Meeting of Stockholders. A total of 13,548,626 shares
of common stock were present in person or represented by proxy at
the meeting, representing approximately 72.9 percent of the
Companys outstanding common stock as of the April 21, 2017 record
date. The following are the voting results for the proposals
considered and voted upon at the meeting, all of which were
described in the Companys Definitive Proxy Statement filed with
the Securities and Exchange Commission on April 25, 2017.
Item 1 – Election of two Class I directors to serve until the
2020 Annual Meeting of Stockholders, and until their respective
successors have been duly elected and qualified.
Votes FOR
Broker Non-Votes
Timothy Springer, Ph.D.
Patrick Zenner
Item 2 – Ratification of the appointment of Ernst Young LLP as
the Companys independent registered public accounting firm for
the year ending December 31, 2017.
Votes FOR
Broker Non-Votes
Based on the foregoing votes, Timothy Springer, Ph.D. and Patrick
Zenner were elected as Class I directors and Item 2 was approved.


Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The Company’s product candidates are in development. The Company’s SVP technology encapsulates an immunomodulator in biodegradable nanoparticles to induce antigen-specific immune tolerance to mitigate the formation of anti-drug antibodies (ADAs) in response to life-sustaining biologic drugs. The Company’s technology allows for the design of SVP therapies that can stimulate immune responses against a range of relevant antigens. Its initial immune-stimulating product candidate is a synthetic vaccine against nicotine for the market of smoking cessation and relapse prevention.

An ad to help with our costs